| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | Il5ra |
| Uniprot No | Q01344 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 21-335aa |
| 氨基酸序列 | DLLPDEKISLLPPVNFTIKVTGLAQVLLQWKPNPDQEQRNVNLEYQVKIN APKEDDYETRITESKCVTILHKGFSASVRTILQNDHSLLASSWASAELHA PPGSPGTSIVNLTCTTNTTEDNYSRLRSYQVSLHCTWLVGTDAPEDTQYF LYYRYGSWTEECQEYSKDTLGRNIACWFPRTFILSKGRDWLAVLVNGSSK HSAIRPFDQLFALHAIDQINPPLNVTAEIEGTRLSIQWEKPVSAFPIHCF DYEVKIHNTRNGYLQIEKLMTNAFISIIDDLSKYDVQVRAAVSSMCREAG LWSEWSQPIYVGNDE |
| 预测分子量 | 38 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于 **IL5RA重组蛋白** 的3篇参考文献示例(部分为模拟内容，实际文献请通过学术数据库检索)：
---
1. **文献名称**: *Structural and Functional Characterization of Recombinant Human IL-5 Receptor α Subunit*
**作者**: Smith A, et al.
**摘要**: 该研究通过X射线晶体学解析了重组人IL5RA的胞外结构域，揭示了其与IL-5结合的分子机制，并证明重组蛋白在体外实验中抑制IL-5介导的嗜酸性粒细胞活化，为靶向治疗提供了结构基础。
2. **文献名称**: *Recombinant Soluble IL5RA Attenuates Asthma Pathology in Murine Models*
**作者**: Lee JH, et al.
**摘要**: 通过表达重组可溶性IL5RA蛋白，研究证明其能够竞争性结合IL-5.阻断下游信号通路，显著减少小鼠模型中气道炎症和嗜酸性粒细胞浸润，提示其作为哮喘治疗的潜在生物制剂。
3. **文献名称**: *Expression and Purification of Functional IL5RA in a Baculovirus System*
**作者**: Wang Q, et al.
**摘要**: 本文优化了IL5RA重组蛋白在杆状病毒表达系统中的生产与纯化流程，验证了其与IL-5的高亲和力结合活性，为大规模制备用于临床前研究的IL5RA提供了技术参考。
---
如需具体文献，建议在 **PubMed** 或 **Google Scholar** 中检索关键词：`recombinant IL5RA protein`、`IL5RA signaling`、`IL-5 receptor structure`。
The interleukin-5 receptor alpha (IL5RA), also known as CD125. is a key component of the type I cytokine receptor family. It specifically binds interleukin-5 (IL-5), a pleiotropic cytokine critical for the differentiation, survival, and activation of eosinophils, which play roles in immune responses against parasites and in allergic inflammation. IL5RA pairs with the common beta chain (βc, shared with IL-3 and GM-CSF receptors) to form a functional receptor complex. Upon IL-5 binding, the receptor triggers JAK-STAT, MAPK, and PI3K signaling pathways, driving eosinophil proliferation and effector functions.
Recombinant IL5RA proteins are engineered versions of the extracellular domain of IL5RA, typically produced in mammalian expression systems (e.g., CHO or HEK293 cells) to ensure proper glycosylation and structural integrity. These soluble receptors retain high affinity for IL-5 and are used as research tools to study IL-5/IL5RA interactions, block IL-5 signaling in vitro, or develop therapeutic strategies. Notably, dysregulated IL-5 signaling is implicated in eosinophilic disorders such as asthma, chronic rhinosinusitis with nasal polyps, and hypereosinophilic syndrome. Therapeutic monoclonal antibodies targeting IL-5 or IL5RA (e.g., mepolizumab, benralizumab) have been developed, highlighting the receptor's clinical relevance.
Recombinant IL5RA proteins also serve as standards in immunoassays, reagents for structural studies (e.g., crystallography), and candidates for fusion proteins designed to neutralize IL-5 in inflammatory diseases. Their development underscores the importance of IL-5 pathway modulation in both basic research and biopharmaceutical applications.
×
